Development of a recombinant human collagen-type III based hemostat.
Development of a recombinant human collagen-type III based hemostat.
复制标题
DOI：
10.1002/jbm.b.20030
复制
发表时间：
2004-04
期刊：
影响因子：
--
通讯作者：
C. Yang;P. Hillas;J. Tang;J. Balan;H. Notbohm;J. Polarek
中科院分区：
文献类型：
--
作者：
C. Yang;P. Hillas;J. Tang;J. Balan;H. Notbohm;J. Polarek
动物组织来源的胶原蛋白主要含有I型胶原蛋白和少量III型胶原蛋白，几十年来已广泛用于生产止血剂，尽管长期以来已知III型胶原蛋白更可能在体外诱导血小板聚集。因为很难从动物组织中纯化III型，所以不可能将这一发现与体内数据相关联。在这份报告中，它表明，重组人胶原蛋白III原纤维更能够诱导血小板聚集在体外比那些由牛胶原蛋白I，与以前发表的数据组织来源的III型胶原蛋白。当形成三维基质时，与市售的由牛I型胶原形成的止血剂相比，III型胶原的使用导致制剂在兔脾损伤模型中具有更好的机械完整性、更大的表面积和更高的止血活性。
Animal-tissue-derived collagen, containing mostly type I collagen with a minor amount of type III collagen, has been widely used in the production of hemostats for many decades, although it has been known for a long time that type III collagen is more likely to induce platelet aggregation in vitro. Because it is hard to purify type III from animal tissue, it has not been possible to correlate this finding with in vivo data. In this report, it is demonstrated that recombinant human collagen III fibrils are more capable of inducing platelet aggregation in vitro than those comprised of bovine collagen I, in agreement with previously published data on tissue-derived type III collagen. When formed into three-dimensional matrices, the use of type III collagen results in formulations with better mechanical integrity, larger surface area, and higher hemostatic activity in a rabbit spleen injury model as compared with commercially available hemostats formed from bovine type I collagen.